^
Association details:
Evidence:
Evidence Level:
Sensitive: C4 – Case Studies
Title:

Osimertinib in non-small cell lung cancer with uncommon EGFR-mutations : a post-hoc subgroup analysis with pooled data from two phase II clinical trials

Published date:
06/29/2023
Excerpt:
Of 299 enrolled patients in the two trials, 21 patients with uncommon mutations were identified; 12 patients had a single mutation (G719X or L861Q), one patient had L861Q and an exon 20 insertion, and 8 patients had compound mutations with G719X and either L861Q or S768I....ORR was 47.6% and disease control rate (DCR) 85.7%. The median duration of response (DoR) was 7.9 months. Among 11 patients treated with osimertinib in first line, ORR was 63.6% vs. 30.0% of 10 previously treated patients. The median PFS was 5.5 months in both groups. Patients with G719X-compound mutations had a higher response rate (62.5% vs. 38.5%), a longer median PFS (13.7 vs. 3.5 months) and median OS (29.3 vs. 7.5 months) than patients with other mutations.
DOI:
10.21037/tlcr-21-995